{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T00:17:35Z","timestamp":1793578655223,"version":"4.5.0"},"reference-count":49,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,4,10]],"date-time":"2026-04-10T00:00:00Z","timestamp":1775779200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T00:00:00Z","timestamp":1779235200000},"content-version":"vor","delay-in-days":40,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100018948","name":"Saudi Arabian Cultural Bureau","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100018948","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Pulm Med"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Low muscle mass, a component of sarcopenia, is increasingly recognised as a marker of poor physiological reserve in chronic diseases. While observed in patients with interstitial lung disease (ILD), its prevalence and clinical associations remain inadequately characterised. Furthermore, heterogeneous diagnostic approaches from CT-derived indices to consensus definitions complicate evidence interpretation.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We conducted a systematic review and meta-analysis to estimate the prevalence of low muscle mass and\/or consensus-defined sarcopenia in ILD. Six databases were searched (1988\u2013March 2024). Eight studies comprising 829 patients (701 with idiopathic pulmonary fibrosis [IPF]) met inclusion criteria. The included CT-based studies defined low muscle mass using cohort-specific lowest-quartile cut-offs, which do not meet consensus diagnostic criteria for sarcopenia.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      The pooled prevalence of low muscle mass and\/or sarcopenia was 24.3% (95% CI: 19.7\u201329.0) with substantial heterogeneity (I\u00b2=59.2%). A sensitivity analysis restricted to consensus-defined sarcopenia yielded a 27.5% prevalence with moderate heterogeneity (I\u00b2=62.5%); however, studies within their respective consensus frameworks (EWGSOP2 or AWGS) demonstrated zero internal heterogeneity (I\u00b2=0%). In contrast, CT-based studies using cohort-specific thresholds showed marked variability (I\u00b2=75.8%). Meta-regression confirmed diagnostic method (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.044) and mean BMI (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.003) as significant moderators. Low muscle mass was significantly associated with reduced pulmonary function, including lower FVC% predicted (effect size\u2009\u2212\u20090.477,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001) and DLCO% predicted (effect size\u2009\u2212\u20090.389,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.003), as well as advancing age and lower BMI.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>While low muscle mass or consensus-defined sarcopenia affects approximately one in four ILD patients, this prevalence is largely representative of the IPF phenotype. Muscle mass abnormalities are significantly associated with respiratory decline, supporting muscle depletion as a clinically relevant marker with potential prognostic implication. However, substantial heterogeneity, driven by CT-based cohort-specific quartiles rather than externally validated thresholds, restricts the precision of current prevalence estimates. Future research should employ standardised consensus definitions, differentiate isolated muscle depletion from systemic wasting syndromes, use externally validated cut-offs, adopt multicentre prospective designs.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12890-026-04255-6","type":"journal-article","created":{"date-parts":[[2026,4,10]],"date-time":"2026-04-10T07:47:05Z","timestamp":1775807225000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Low muscle mass in interstitial lung disease: a systematic review and meta-analysis of prevalence and clinical associations"],"prefix":"10.1186","volume":"26","author":[{"given":"Osamah","family":"Alsuhimi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdullah","family":"Alharbi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wahaj","family":"Alnefaie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Husam","family":"Alahmadi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fatma","family":"Almaghlouth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdullah A.","family":"Alqarni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Davies","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas M.","family":"Gill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean","family":"Woo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carly","family":"Welch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Beatson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Kolb","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John R.","family":"Hurst","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joanna C.","family":"Porter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,10]]},"reference":[{"key":"4255_CR1","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2021.751181","volume":"8","author":"B Kaul","year":"2021","unstructured":"Kaul B, Cottin V, Collard HR, Valenzuela C. Variability in global prevalence of interstitial lung disease. Front Med (Lausanne). 2021;8:751181.","journal-title":"Front Med (Lausanne)"},{"key":"4255_CR2","doi-asserted-by":"publisher","unstructured":"Margaritopoulos GA, Antoniou KM, Wells AU. Comorbidities in interstitial lung diseases. Eur Respir Rev. 2017. https:\/\/doi.org\/10.1183\/16000617.0027-2016.","DOI":"10.1183\/16000617.0027-2016"},{"issue":"1","key":"4255_CR3","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1186\/s12931-022-01981-3","volume":"23","author":"TS Prior","year":"2022","unstructured":"Prior TS, Hyldgaard C, Torrisi SE, Kronborg-White S, Ganter C, Bendstrup E, Kreuter M. Comorbidities in unclassifiable interstitial lung disease. Respir Res. 2022;23(1):59.","journal-title":"Respir Res"},{"issue":"5","key":"4255_CR4","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1016\/j.crad.2024.01.015","volume":"79","author":"S Watson","year":"2024","unstructured":"Watson S, Dixon G, Savill A, Gibbons MA, Barratt SL, Rodrigues JCL. Complications of fibrotic interstitial lung disease for the general radiologist. Clin Radiol. 2024;79(5):323\u20139.","journal-title":"Clin Radiol"},{"key":"4255_CR5","doi-asserted-by":"publisher","first-page":"102587","DOI":"10.1016\/j.arr.2024.102587","volume":"103","author":"M Nunes-Pinto","year":"2025","unstructured":"Nunes-Pinto M, Bandeira de Mello RG, Pinto MN, Moro C, Vellas B, Martinez LO, et al. Sarcopenia and the biological determinants of aging: A narrative review from a geroscience perspective. Ageing Res Rev. 2025;103:102587.","journal-title":"Ageing Res Rev"},{"issue":"4","key":"4255_CR6","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1093\/ageing\/afz046","volume":"48","author":"AJ Cruz-Jentoft","year":"2019","unstructured":"Cruz-Jentoft AJ, Bahat G, Bauer J, Boirie Y, Bruyere O, Cederholm T, et al. Sarcopenia: revised European consensus on definition and diagnosis. Age Ageing. 2019;48(4):601.","journal-title":"Age Ageing"},{"issue":"1","key":"4255_CR7","doi-asserted-by":"publisher","DOI":"10.1186\/s12931-019-1022-1","volume":"20","author":"M Kolb","year":"2019","unstructured":"Kolb M, Vasakova M. The natural history of progressive fibrosing interstitial lung diseases. Respir Res. 2019;20(1):57.","journal-title":"Respir Res"},{"key":"4255_CR8","doi-asserted-by":"publisher","DOI":"10.1186\/2213-0802-2-4","volume":"2","author":"KC Meyer","year":"2014","unstructured":"Meyer KC. Diagnosis and management of interstitial lung disease. Transl Respir Med. 2014;2:4.","journal-title":"Transl Respir Med"},{"issue":"3","key":"4255_CR9","first-page":"289","volume":"2","author":"RC Wust","year":"2007","unstructured":"Wust RC, Degens H. Factors contributing to muscle wasting and dysfunction in COPD patients. Int J Chron Obstruct Pulmon Dis. 2007;2(3):289\u2013300.","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"key":"4255_CR10","doi-asserted-by":"publisher","first-page":"865402","DOI":"10.3389\/fnut.2022.865402","volume":"9","author":"FG Di Girolamo","year":"2022","unstructured":"Di Girolamo FG, Fiotti N, Sisto UG, Nunnari A, Colla S, Mearelli F, et al. Skeletal Muscle in Hypoxia and Inflammation: Insights on the COVID-19 Pandemic. Front Nutr. 2022;9:865402.","journal-title":"Front Nutr"},{"issue":"1","key":"4255_CR11","doi-asserted-by":"publisher","first-page":"14074","DOI":"10.1038\/s41598-018-32478-z","volume":"8","author":"Y Suzuki","year":"2018","unstructured":"Suzuki Y, Yoshimura K, Enomoto Y, Yasui H, Hozumi H, Karayama M, et al. Distinct profile and prognostic impact of body composition changes in idiopathic pulmonary fibrosis and idiopathic pleuroparenchymal fibroelastosis. Sci Rep. 2018;8(1):14074.","journal-title":"Sci Rep"},{"issue":"1","key":"4255_CR12","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1620\/tjem.253.61","volume":"253","author":"K Ebihara","year":"2021","unstructured":"Ebihara K, Iwanami Y, Yamasaki K, Takemura A, Sato N, Usui Y, et al. Appendicular Skeletal Muscle Mass Correlates with Patient-Reported Outcomes and Physical Performance in Patients with Idiopathic Pulmonary Fibrosis. Tohoku J Exp Med. 2021;253(1):61\u20138.","journal-title":"Tohoku J Exp Med"},{"issue":"1","key":"4255_CR13","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1186\/s12931-019-1019-9","volume":"20","author":"SA Guler","year":"2019","unstructured":"Guler SA, Hur SA, Lear SA, Camp PG, Ryerson CJ. Body composition, muscle function, and physical performance in fibrotic interstitial lung disease: a prospective cohort study. Respir Res. 2019;20(1):56.","journal-title":"Respir Res"},{"issue":"12","key":"4255_CR14","doi-asserted-by":"publisher","first-page":"1113","DOI":"10.1007\/s40266-025-01252-y","volume":"42","author":"E Papadopoulos","year":"2025","unstructured":"Papadopoulos E, Irving BA, Brown JC, Heymsfield SB, Sattar S, Alibhai SMH, et al. Sarcopenia and Cachexia in Older Patients with Cancer: Pathophysiology, Diagnosis, Impact on Outcomes, and Management Strategies. Drugs Aging. 2025;42(12):1113\u201342.","journal-title":"Drugs Aging"},{"key":"4255_CR15","doi-asserted-by":"publisher","unstructured":"Sanmartin-Sanchez A, Fernandez-Jimenez R, Olivares-Alcolea J, Cabrera-Cesar E, Espildora-Hernandez F, Vegas-Aguilar I. Cachexia Phenotyping Through Morphofunctional Assessment and Mitocondrial Biomarkers (GDF-15 and PGC-1alpha) in Idiopathic Pulmonary Fibrosis. Nutrients. 2025. https:\/\/doi.org\/10.3390\/nu17172739.","DOI":"10.3390\/nu17172739"},{"key":"4255_CR16","doi-asserted-by":"publisher","first-page":"152366","DOI":"10.1016\/j.semarthrit.2024.152366","volume":"65","author":"C Sieiro Santos","year":"2024","unstructured":"Sieiro Santos C, Antolin SC, Lorenzo JC, Garay CL, Morales CM, de Miguel EB, et al. KL6 and IL-18 levels are negatively correlated with respiratory function tests and ILD extent assessed on HRCT in patients with systemic sclerosis-related interstitial lung disease (SSc-ILD). Semin Arthritis Rheum. 2024;65:152366.","journal-title":"Semin Arthritis Rheum"},{"key":"4255_CR17","doi-asserted-by":"publisher","unstructured":"Ruaro B, Baratella E, Confalonieri P, Wade B, Marrocchio C, Geri P, et al. High-Resolution Computed Tomography: Lights and Shadows in Improving Care for SSc-ILD Patients. Diagnostics. 2021. https:\/\/doi.org\/10.3390\/diagnostics11111960.","DOI":"10.3390\/diagnostics11111960"},{"key":"4255_CR18","doi-asserted-by":"publisher","unstructured":"Osadnik CR, Brighton LJ, Burtin C, Cesari M, Lahousse L, Man WDC, et al. European Respiratory Society statement on frailty in adults with chronic lung disease. Eur Respir J. 2023. https:\/\/doi.org\/10.1183\/13993003.00442-2023.","DOI":"10.1183\/13993003.00442-2023"},{"key":"4255_CR19","doi-asserted-by":"publisher","first-page":"106184","DOI":"10.1016\/j.rmed.2020.106184","volume":"174","author":"M Hanada","year":"2020","unstructured":"Hanada M, Ishimatsu Y, Sakamoto N, Nagura H, Oikawa M, Morimoto Y, et al. Corticosteroids are associated with reduced skeletal muscle function in interstitial lung disease patients with mild dyspnea. Respir Med. 2020;174:106184.","journal-title":"Respir Med"},{"issue":"1","key":"4255_CR20","doi-asserted-by":"publisher","DOI":"10.1186\/s13643-016-0384-4","volume":"5","author":"M Ouzzani","year":"2016","unstructured":"Ouzzani M, Hammady H, Fedorowicz Z, Elmagarmid A. Rayyan-a web and mobile app for systematic reviews. Syst Rev. 2016;5(1):210.","journal-title":"Syst Rev"},{"issue":"3","key":"4255_CR21","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1016\/j.eururo.2020.12.017","volume":"79","author":"JM Norris","year":"2021","unstructured":"Norris JM, Simpson BS, Ball R, Freeman A, Kirkham A, Parry MA, et al. A Modified Newcastle-Ottawa Scale for Assessment of Study Quality in Genetic Urological Research. Eur Urol. 2021;79(3):325\u20136.","journal-title":"Eur Urol"},{"key":"4255_CR22","unstructured":"Ga W, editor. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. In 3rd Symposium on Systematic Reviews: Beyond the Basics, Oxford, UK, 3-5 July 2000."},{"key":"4255_CR23","doi-asserted-by":"publisher","first-page":"1","DOI":"10.18637\/jss.v049.i05","volume":"49","author":"BC Wallace","year":"2012","unstructured":"Wallace BC, Dahabreh IJ, Trikalinos TA, Lau J, Trow P, Schmid CH. Closing the gap between methodologists and end-users: R as a computational back-end. J Stat Softw. 2012;49:1\u201315.","journal-title":"J Stat Softw"},{"issue":"6","key":"4255_CR24","doi-asserted-by":"publisher","first-page":"1785","DOI":"10.1177\/0962280216669183","volume":"27","author":"D Luo","year":"2018","unstructured":"Luo D, Wan X, Liu J, Tong T. Optimally estimating the sample mean from the sample size, median, mid-range, and\/or mid-quartile range. Stat Methods Med Res. 2018;27(6):1785\u2013805.","journal-title":"Stat Methods Med Res"},{"key":"4255_CR25","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2288-14-135","volume":"14","author":"X Wan","year":"2014","unstructured":"Wan X, Wang W, Liu J, Tong T. Estimating the sample mean and standard deviation from the sample size, median, range and\/or interquartile range. BMC Med Res Methodol. 2014;14:135.","journal-title":"BMC Med Res Methodol"},{"issue":"11","key":"4255_CR26","doi-asserted-by":"publisher","first-page":"1539","DOI":"10.1002\/sim.1186","volume":"21","author":"JP Higgins","year":"2002","unstructured":"Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med. 2002;21(11):1539\u201358.","journal-title":"Stat Med"},{"issue":"7109","key":"4255_CR27","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1136\/bmj.315.7109.629","volume":"315","author":"M Egger","year":"1997","unstructured":"Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997;315(7109):629\u201334.","journal-title":"BMJ"},{"key":"4255_CR28","doi-asserted-by":"publisher","first-page":"n71","DOI":"10.1136\/bmj.n71","volume":"372","author":"MJ Page","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372:n71.","journal-title":"BMJ"},{"key":"4255_CR29","volume":"82","author":"T Fujikawa","year":"2022","unstructured":"Fujikawa T, Kondo S, Saito T, Inoue T, Otake K, Misu S, et al. Impact of sarcopenia defined by carina-level skeletal muscle mass on the long-term prognosis of patients with idiopathic pulmonary fibrosis. Respir Med Res. 2022;82:100965.","journal-title":"Respir Med Res"},{"issue":"12","key":"4255_CR30","doi-asserted-by":"publisher","first-page":"904","DOI":"10.1016\/j.crad.2023.08.011","volume":"78","author":"A \u00c7inkoo\u011flu","year":"2023","unstructured":"\u00c7inkoo\u011flu A, Bayraktaro\u011flu S, Ufuk F, Unat \u00d6S, K\u00f6se T, Sava\u015f R, Bishop NM. Reduced CT-derived erector spinae muscle area: a poor prognostic factor for short-and long-term outcomes in idiopathic pulmonary fibrosis patients. Clin Radiol. 2023;78(12):904\u201311.","journal-title":"Clin Radiol"},{"key":"4255_CR31","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12931-019-1001-6","volume":"20","author":"SW Moon","year":"2019","unstructured":"Moon SW, Choi JS, Lee SH, Jung KS, Jung JY, Kang YA, et al. Thoracic skeletal muscle quantification: low muscle mass is related with worse prognosis in idiopathic pulmonary fibrosis patients. Respir Res. 2019;20:1\u20139.","journal-title":"Respir Res"},{"issue":"1","key":"4255_CR32","doi-asserted-by":"publisher","DOI":"10.1186\/s12931-022-02159-7","volume":"23","author":"P Faverio","year":"2022","unstructured":"Faverio P, Fumagalli A, Conti S, Madotto F, Bini F, Harari S, et al. Sarcopenia in idiopathic pulmonary fibrosis: a prospective study exploring prevalence, associated factors and diagnostic approach. Respir Res. 2022;23(1):228.","journal-title":"Respir Res"},{"issue":"1","key":"4255_CR33","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1186\/s12890-022-01840-3","volume":"22","author":"M Hanada","year":"2022","unstructured":"Hanada M, Sakamoto N, Ishimoto H, Kido T, Miyamura T, Oikawa M, et al. A comparative study of the sarcopenia screening in older patients with interstitial lung disease. BMC Pulm Med. 2022;22(1):45.","journal-title":"BMC Pulm Med"},{"key":"4255_CR34","doi-asserted-by":"publisher","DOI":"10.1177\/14799731221117298","volume":"19","author":"K Fujita","year":"2022","unstructured":"Fujita K, Ohkubo H, Nakano A, Mori Y, Fukumitsu K, Fukuda S, et al. Frequency and impact on clinical outcomes of sarcopenia in patients with idiopathic pulmonary fibrosis. Chron Respir Dis. 2022;19:14799731221117298.","journal-title":"Chron Respir Dis"},{"key":"4255_CR35","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.nutos.2024.01.003","volume":"54","author":"A Alarc\u00f3n-Dionet","year":"2024","unstructured":"Alarc\u00f3n-Dionet A, Osuna-Padilla IA, Rodriguez-D\u00edaz Z, del Valle-Alegr\u00eda GRG, Tellez-Quijada F, Martinez-Rodriguez Y, et al. Nutritional status and body composition in female patients with interstitial lung diseases. Clin Nutr Open Sci. 2024;54:41\u201350.","journal-title":"Clin Nutr Open Sci"},{"issue":"1","key":"4255_CR36","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1186\/s12931-024-02705-5","volume":"25","author":"M Sridhar","year":"2024","unstructured":"Sridhar M, Bodduluri S, O\u2019Hare L, Blumhoff S, de Acosta Lara MdP JA, et al. Association of musculoskeletal involvement with lung function and mortality in patients with idiopathic pulmonary fibrosis. Respir Res. 2024;25(1):81.","journal-title":"Respir Res"},{"key":"4255_CR37","doi-asserted-by":"publisher","first-page":"1187760","DOI":"10.3389\/fmed.2023.1187760","volume":"10","author":"J Li","year":"2023","unstructured":"Li J, Lu Y, Deng M, Tong R, Zhang Q, Bian Y, et al. Prevalence and risk factors of sarcopenia in idiopathic pulmonary fibrosis: a systematic review and meta-analysis. Front Med (Lausanne). 2023;10:1187760.","journal-title":"Front Med (Lausanne)"},{"issue":"8","key":"4255_CR38","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1016\/j.jamda.2016.06.001","volume":"17","author":"L Cao","year":"2016","unstructured":"Cao L, Morley JE. Sarcopenia is recognized as an independent condition by an international classification of disease, tenth revision, clinical modification (ICD-10-CM) code. J Am Med Dir Assoc. 2016;17(8):675\u20137.","journal-title":"J Am Med Dir Assoc"},{"issue":"1","key":"4255_CR39","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-020-75250-y","volume":"10","author":"V Therakomen","year":"2020","unstructured":"Therakomen V, Petchlorlian A, Lakananurak N. Prevalence and risk factors of primary sarcopenia in community-dwelling outpatient elderly: a cross-sectional study. Sci Rep. 2020;10(1):19551.","journal-title":"Sci Rep"},{"issue":"1","key":"4255_CR40","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1002\/jcsm.13161","volume":"14","author":"AK Stuck","year":"2023","unstructured":"Stuck AK, Basile G, Freystaetter G, de Godoi Rezen Costa Molino C, Lang W, Bischoff-Ferrari HA. Predictive validity of current sarcopenia definitions (EWGSOP2, SDOC, and AWGS2) for clinical outcomes: a scoping review. J Cachexia Sarcopenia Muscle. 2023;14(1):71\u201383.","journal-title":"J Cachexia Sarcopenia Muscle"},{"key":"4255_CR41","doi-asserted-by":"publisher","DOI":"10.3389\/fnut.2024.1342113","volume":"11","author":"W Xu","year":"2024","unstructured":"Xu W, Mu D, Wang Y, Wang Y, Wang C, Zhang X. Association between oxidative balance score and sarcopenia in US adults: NHANES 2011-2018. Front Nutr. 2024;11:1342113.","journal-title":"Front Nutr"},{"issue":"1","key":"4255_CR42","doi-asserted-by":"publisher","first-page":"10367","DOI":"10.1038\/s41598-023-37229-3","volume":"13","author":"LA da Costa Teixeira","year":"2023","unstructured":"da Costa Teixeira LA, Avelar NCP, Peixoto MFD, Parentoni AN, Santos JMD, Pereira FSM, et al. Inflammatory biomarkers at different stages of Sarcopenia in older women. Sci Rep. 2023;13(1):10367.","journal-title":"Sci Rep"},{"issue":"9","key":"4255_CR43","doi-asserted-by":"publisher","first-page":"11802","DOI":"10.1096\/fj.202001045RR","volume":"34","author":"B Ng","year":"2020","unstructured":"Ng B, Dong J, Viswanathan S, Widjaja AA, Paleja BS, Adami E, et al. Fibroblast-specific IL11 signaling drives chronic inflammation in murine fibrotic lung disease. FASEB J. 2020;34(9):11802\u201315.","journal-title":"FASEB J"},{"issue":"7","key":"4255_CR44","doi-asserted-by":"publisher","first-page":"1028","DOI":"10.1016\/j.bbadis.2012.11.021","volume":"1832","author":"P Cheresh","year":"2013","unstructured":"Cheresh P, Kim SJ, Tulasiram S, Kamp DW. Oxidative stress and pulmonary fibrosis. Biochim Biophys Acta. 2013;1832(7):1028\u201340.","journal-title":"Biochim Biophys Acta"},{"key":"4255_CR45","doi-asserted-by":"publisher","first-page":"601279","DOI":"10.3389\/fmed.2020.601279","volume":"7","author":"G Leuschner","year":"2020","unstructured":"Leuschner G, Klotsche J, Kreuter M, Prasse A, Wirtz H, Pittrow D, et al. Idiopathic Pulmonary Fibrosis in Elderly Patients: Analysis of the INSIGHTS-IPF Observational Study. Front Med (Lausanne). 2020;7:601279.","journal-title":"Front Med (Lausanne)"},{"key":"4255_CR46","doi-asserted-by":"publisher","unstructured":"Shenderov K, Collins SL, Powell JD, Horton MR. Immune dysregulation as a driver of idiopathic pulmonary fibrosis. J Clin Invest. 2021. https:\/\/doi.org\/10.1172\/JCI143226.","DOI":"10.1172\/JCI143226"},{"issue":"4","key":"4255_CR47","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1016\/j.resinv.2023.02.010","volume":"61","author":"Y Ito","year":"2023","unstructured":"Ito Y, Anan K, Awano N, Kataoka Y, Johkoh T, Fujimoto K, et al. Skeletal muscle atrophy and short-term mortality in patients with acute exacerbation of idiopathic pulmonary fibrosis: an observational cohort study. Respir Investig. 2023;61(4):371\u20138.","journal-title":"Respir Investig"},{"issue":"2","key":"4255_CR48","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1111\/resp.13943","volume":"26","author":"Y Suzuki","year":"2021","unstructured":"Suzuki Y, Aono Y, Kono M, Hasegawa H, Yokomura K, Naoi H, et al. Cause of mortality and sarcopenia in patients with idiopathic pulmonary fibrosis receiving antifibrotic therapy. Respirology. 2021;26(2):171\u20139.","journal-title":"Respirology"},{"issue":"9","key":"4255_CR49","doi-asserted-by":"publisher","first-page":"1046","DOI":"10.1038\/ejcn.2016.73","volume":"70","author":"AS Sousa","year":"2016","unstructured":"Sousa AS, Guerra RS, Fonseca I, Pichel F, Ferreira S, Amaral TF. Financial impact of sarcopenia on hospitalization costs. Eur J Clin Nutr. 2016;70(9):1046\u201351.","journal-title":"Eur J Clin Nutr"}],"container-title":["BMC Pulmonary Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12890-026-04255-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12890-026-04255-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12890-026-04255-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T21:45:17Z","timestamp":1781646317000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12890-026-04255-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,10]]},"references-count":49,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["4255"],"URL":"https:\/\/doi.org\/10.1186\/s12890-026-04255-6","relation":{},"ISSN":["1471-2466"],"issn-type":[{"value":"1471-2466","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,10]]},"assertion":[{"value":"28 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Competing interests: Dr. Joanna Porter reports receiving a grant from Boehringer Ingelheim. Dr. Martin Kolb reports grants from the Canadian Institute for Health Research, Boehringer Ingelheim, United Therapeutics, and Structure Therapeutics; and personal fees from Boehringer Ingelheim, Roche, European Respiratory Journal, Fortrea, United Therapeutics, Abbvie, Avalyn, DevPro Biopharma, Horizon\/Amgen, CSL Behring, AstraZeneca, GlaxoSmithKline, Sanofi, Structure Therapeutics, and Glenmark.No other authors have any conflicts of interest to declare.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"229"}}